Fluoroquinolones and Aortic Diseases: Is There a Connection

Abstract

Fluoroquinolones (FQs) are one of the most commonly prescribed classes of antibiotics. Their high tissue distribution and broad-spectrum antibacterial coverage make their use very attractive in numerous infectious diseases. Although generally well tolerated, FQs have been associated with different adverse effects including dysglycemia and arrhythmias. FQs have been also associated with a series of adverse effects related to collagen degradation, such as Achilles tendon rupture and retinal detachment. Recently, an association between consumption of FQs and increased risk of aortic aneurysm and dissection has been proposed. This article reviews the pathogenesis of thoracic aortic diseases, the molecular mechanism of FQ-associated collagen toxicity, and the possible contribution of FQs to aortic diseases.

Keywords

aortic disease - aortic dissection - fluoroquinolones

• References

• 1 Zhanel GG, Walkty A, Vercaigne L. , et al. The new fluoroquinolones: a critical review. Can J Infect Dis 1999; 10 (03) 207-238
• 2 Zhanel GG, Ennis K, Vercaigne L. , et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62 (01) 13-59
• 3 Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118 (03) 259-268
• 4 Mamdani M, McNeely D, Evans G. , et al. Impact of a fluoroquinolone restriction policy in an elderly population. Am J Med 2007; 120 (10) 893-900
• 5 Owens Jr RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl. 02) S144-S157
• 6 Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29 (04) 374-379
• 7 Bailey RR, Kirk JA, Peddie BA. Norfloxacin-induced rheumatic disease. N Z Med J 1983; 96 (736) 590
• 8 Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012; 125 (12) 1228.e23-1228.e28
• 9 Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 2015; 5 (11) e010077
• 10 van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163 (15) 1801-1807
• 11 Ponsioen TL, van Luyn MJ, van der Worp RJ, van Meurs JC, Hooymans JM, Los LI. Collagen distribution in the human vitreoretinal interface. Invest Ophthalmol Vis Sci 2008; 49 (09) 4089-4095
• 12 Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012; 307 (13) 1414-1419
• 13 Chui CS, Man KK, Cheng CL. , et al. An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study. J Antimicrob Chemother 2014; 69 (09) 2563-2567
• 14 Lee CC, Lee MT, Chen YS. , et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med 2015; 175 (11) 1839-1847
• 15 Lee CC, Lee MG, Hsieh R. , et al. Oral fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol 2018; 72 (12) 1369-1378
• 16 Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018; 360: k678
• 17 O'Brien M. Functional anatomy and physiology of tendons. Clin Sports Med 1992; 11 (03) 505-520
• 18 Amiel D, Frank C, Harwood F, Fronek J, Akeson W. Tendons and ligaments: a morphological and biochemical comparison. J Orthop Res 1984; 1 (03) 257-265
• 19 Tsai WC, Hsu CC, Chen CP. , et al. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res 2011; 29 (01) 67-73
• 20 Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3 (03) 207-214
• 21 Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74 (02) 111-122
• 22 Mayne R. Collagenous proteins of blood vessels. Arteriosclerosis 1986; 6 (06) 585-593
• 23 Halushka MK. Chapter 13 - Genetic diseases of the aorta (including aneurysms) A2 - Willis, Monte S. In: Homeister JW, Stone JR. , eds. Cellular and Molecular Pathobiology of Cardiovascular Disease. San Diego, CA: Academic Press; 2014: 239-255
• 24 Humphrey JD. Possible mechanical roles of glycosaminoglycans in thoracic aortic dissection and associations with dysregulated transforming growth factor-β. J Vasc Res 2013; 50 (01) 1-10
• 25 Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin 1999; 17 (04) 615-635 , vii.
• 26 Koullias G, Modak R, Tranquilli M, Korkolis DP, Barash P, Elefteriades JA. Mechanical deterioration underlies malignant behavior of aneurysmal human ascending aorta. J Thorac Cardiovasc Surg 2005; 130 (03) 677-683
• 27 Ziganshin BA, Elefteriades JA. Yale milestones in reading the playbook of thoracic aortic aneurysms. Conn Med 2012; 76 (10) 589-598
• 28 Scholl FG, Coady MA, Davies R. , et al. Interval or permanent nonoperative management of acute type A aortic dissection. Arch Surg 1999; 134 (04) 402-405 , discussion 405–406
• 29 Albornoz G, Coady MA, Roberts M. , et al. Familial thoracic aortic aneurysms and dissections-incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg 2006; 82 (04) 1400-1405
• 30 Elefteriades JA. Thoracic aortic aneurysm: reading the enemy's playbook. World J Surg 2008; 32 (03) 366-374
• 31 Biddinger A, Rocklin M, Coselli J, Milewicz DM. Familial thoracic aortic dilatations and dissections: a case control study. J Vasc Surg 1997; 25 (03) 506-511
• 32 Koullias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteriades JA. Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg 2004; 78 (06) 2106-2110 , discussion 2110–2111
• 33 LeMaire SA, Wang X, Wilks JA. , et al. Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves. J Surg Res 2005; 123 (01) 40-48
• 34 Ikonomidis JS, Jones JA, Barbour JR. , et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg 2007; 133 (04) 1028-1036
• 35 Elefteriades JA, Hatzaras I, Tranquilli MA. , et al. Weight lifting and rupture of silent aortic aneurysms. JAMA 2003; 290 (21) 2803
• 36 Hatzaras I, Tranquilli M, Coady M, Barrett PM, Bible J, Elefteriades JA. Weight lifting and aortic dissection: more evidence for a connection. Cardiology 2007; 107 (02) 103-106
• 37 Hatzaras IS, Bible JE, Koullias GJ, Tranquilli M, Singh M, Elefteriades JA. Role of exertion or emotion as inciting events for acute aortic dissection. Am J Cardiol 2007; 100 (09) 1470-1472
• 38 Williams III RJ, Attia E, Wickiewicz TL, Hannafin JA. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 2000; 28 (03) 364-369
• 39 Shakibaei M, Pfister K, Schwabe R, Vormann J, Stahlmann R. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother 2000; 44 (02) 261-266
• 40 Sendzik J, Shakibaei M, Schäfer-Korting M, Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology 2005; 212 (01) 24-36
• 41 Sendzik J, Shakibaei M, Schäfer-Korting M, Lode H, Stahlmann R. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents 2010; 35 (04) 366-374
• 42 LeMaire SA, Zhang L, Luo W. , et al. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg 2018; 153 (09) e181804
• 43 Tam PK, Ho CT. Fluoroquinolone-induced Achilles tendinitis. Hong Kong Med J 2014; 20 (06) 545-547
• 44 Corrao G, Zambon A, Bertù L. , et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf 2006; 29 (10) 889-896
• 45 van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324 (7349): 1306-1307
• 46 Schwald N, Debray-Meignan S. Suspected role of ofloxacin in a case of arthralgia, myalgia, and multiple tendinopathy. Rev Rhum Engl Ed 1999; 66 (7-9): 419-421
• 47 Tsai WC, Yang YM. Fluoroquinolone-associated tendinopathy. Chang Gung Med J 2011; 34 (05) 461-467
• 48 Yu C, Giuffre B. Achilles tendinopathy after treatment with fluoroquinolone. Australas Radiol 2005; 49 (05) 407-410
• 49 Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36 (11) 1404-1410
• 50 Kuo SC, Chen YT, Lee YT. , et al. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study. Clin Infect Dis 2014; 58 (02) 197-203
• 51 Akhtar S, Meek KM, James V. Ultrastructure abnormalities in proteoglycans, collagen fibrils, and elastic fibers in normal and myxomatous mitral valve chordae tendineae. Cardiovasc Pathol 1999; 8 (04) 191-201
• 52 Akhtar S, Meek KM, James V. Immunolocalization of elastin, collagen type I and type III, fibronectin, and vitronectin in extracellular matrix components of normal and myxomatous mitral heart valve chordae tendineae. Cardiovasc Pathol 1999; 8 (04) 203-211
• 53 Moesgaard SG, Aupperle H, Rajamäki MM. , et al. Matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and transforming growth factor-β (TGF-β) in advanced canine myxomatous mitral valve disease. Res Vet Sci 2014; 97 (03) 560-567
• 54 Aupperle H, Thielebein J, Kiefer B. , et al. Expression of genes encoding matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in normal and diseased canine mitral valves. J Comp Pathol 2009; 140 (04) 271-277
• 55 Balistreri CR, Allegra A, Crapanzano F. , et al. Associations of rs3918242 and rs2285053 MMP-9 and MMP-2 polymorphisms with the risk, severity, and short- and long-term complications of degenerative mitral valve diseases: a 4.8-year prospective cohort study. Cardiovasc Pathol 2016; 25 (05) 362-370
• 56 Dreger SA, Taylor PM, Allen SP, Yacoub MH. Profile and localization of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in human heart valves. J Heart Valve Dis 2002; 11 (06) 875-880 , discussion 880
• 57 Icardo JM, Colvee E, Revuelta JM. Structural analysis of chordae tendineae in degenerative disease of the mitral valve. Int J Cardiol 2013; 167 (04) 1603-1609
• 58 Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. 2016 http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm126085.htm . (Accessed January 16, 2016)
• 59 European Medicines Agency Pharmacovigilance Risk Assessment Committee. Recommendation on Signals. 2018 https://www.ema.europa.eu/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf . (Accessed February 18, 2019)
• 60 US Food and Drug Administration. Safety Announcement. 2018 https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm . (Accessed February 18, 2019)